Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398567 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase 1 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00398567 is a Phase 1 study that has completed, run by Puma Biotechnology. The registered enrollment target is 45 participants.
The verdict
NCT00398567, a Phase 1 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of HKI-272 (neratinib) in combination with trastuzumab in patients with advanced breast cancer.
Interventions
- DRUG trastuzumab
- DRUG HKI-272
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-04-04 |
| Est. Completion | 2018-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398567
The ClinicalTrials.gov registry entry for NCT00398567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which trastuzumab is the first listed.
NCT00398567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398567 about?
NCT00398567 is a clinical study titled "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer". The purpose of this study is to determine the safety and efficacy of HKI-272 (neratinib) in combination with trastuzumab in patients with advanced breast cancer.
What is the current status of trial NCT00398567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2007-04-04. Estimated completion is 2018-03-02.
What interventions are being tested in trial NCT00398567?
The interventions under investigation include: trastuzumab (DRUG), HKI-272 (DRUG).
Who is sponsoring clinical trial NCT00398567?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.